18F-FDG PET/CT May Predict Tumor Type and Risk Score in Gestational Trophoblastic Disease

Bezzi, Carolina; Monaco, Lavinia; Ghezzo, Samuele; Mathoux, Gregory; Bergamini, Alice; Zambella, Enrica; Fallanca, Federico; Gajate, Ana Maria Samanes; Presotto, Luca; Sabetta, G.; Mangili, Giorgia; Cioffi, Raffaella; Bettinardi, Valentino; Mapelli, Paola; Picchio, Maria

doi:10.1097/rlu.0000000000004135

Cited by 6 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have malignant potential, and it is widely accepted that a diameter of GIST ≥ 20 mm should be treated [8]. The diagnosis of GIST originates from the development of molecular biology, and needs to be determined by combining histological findings and immunohistochemical results [9,10]. The biological risk of GIST is closely related to the location, size, shape, density, presence or absence of necrotic cystic degeneration and calcification, presence or absence of ulceration, invasive growth and the blood supply of the tumor; but the most critical factor in determining the biological risk of GIST is its histological mitotic number, which is the proliferation state and activity of the cell.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors

et al. 2022

View full text Add to dashboard Cite

Objectives To explore the clinical significance of 18F-FDG metabolic imaging in the diagnosis and biological risk assessment of gastrointestinal stromal tumors (GIST). Methods This study is a clinical retrospective study. The research subjects were patients with GIST who were admitted to our hospital from January 2014 to December 2019 and underwent 18F-FDG metabolic imaging, and the relationship between biological risk and FDG metabolism was analyzed retrospectively. Results A total of 32 patients with GIST were included in this study, of which 17 patients had very low and low-risk lesions, and the FDG metabolism level did not increase; five patients had moderate-risk gastric lesions, and the FDG metabolism level was abnormally increased; 10 patients had high-risk lesions, and except for one patient with multiple lesions, the FDG metabolism level of these patients was increased. Conclusions The level of glucose metabolism is abnormally increased in tumor cells with vigorous mitosis and has higher biological risk. The 18F-FDG metabolism level can determine the biological risk of GIST and whether high-risk lesions involve other tissues and organs, as it more comprehensively reflects the distribution of lesions, the activity of tumor cells and the stage of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…18 F-FDG PET/CT is far superior to other imaging modalities in its sensitivity for detecting aggressive cutaneous lesions, suggesting great potential in the clinic. Several studies have attempted to delineate a methodology for using 18 F-FDG PET/CT to generate a global disease score [32,[36][37][38] A singular score generated at every follow-up visit may simplify assessment of disease progression, as well as predict the prognosis of disease in patients with PCL. Although a global disease score is a potentially useful clinical parameter, the method is limited by its lack of technical standardization and external validation.…”

Section: Treatment Response Evaluationmentioning

confidence: 99%

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

et al. 2023

View full text Add to dashboard Cite

Introduction Primary cutaneous lymphoma (PCL) is a cutaneous non-Hodgkin’s lymphoma that originates in the skin and lacks extracutaneous spread upon initial diagnosis. The clinical management of secondary cutaneous lymphomas is different from that of PCLs, and earlier detection is associated with better prognosis. Accurate staging is necessary to determine the extent of disease and to choose the appropriate treatment. The aim of this review is to investigate the current and potential roles of 18F- fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET/CT) in the diagnosis, staging, and monitoring of PCLs. Methods A focused review of the scientific literature was performed using inclusion criteria to filter results pertaining to human clinical studies performed between 2015 and 2021 that analyzed cutaneous PCL lesions on 18F PET/CT imaging. Results & Conclusion A review of 9 clinical studies published after 2015 concluded that 18F-FDG PET/CT is highly sensitive and specific for aggressive PCLs and proved valuable for identifying extracutaneous disease. These studies found 18F-FDG PET/CT highly useful for guiding lymph node biopsy and that imaging results influenced therapeutic decision in many cases. These studies also predominantly concluded that 18F-FDG PET/CT is more sensitive than computed tomography (CT) alone for detection of subcutaneous PCL lesions. Routine revision of nonattenuation-corrected (NAC) PET images may improve the sensitivity of 18F-FDG PET/CT for detection of indolent cutaneous lesions and may expand the potential uses of 18F-FDG PET/CT in the clinic. Furthermore, calculating a global disease score from 18F-FDG PET/CT at every follow-up visit may simplify assessment of disease progression in the early clinical stages, as well as predict the prognosis of disease in patients with PCL.

show abstract

“…However, the estimation of quantitative data such as imaging-derived parameters has recently attracted great interest [31] and is currently under evaluation as an innovative tool for improving disease characterization and tumour heterogeneity [32]. With respect to 18 F-FDG PET images, standardized uptake value maximum and mean (SU-Vmax, SUVmean), metabolic tumour volume (MTV), and total lesion glycolysis (TLG) are among the most encountered and investigated parameters, now recognized as biomarkers of pathophysiological processes in several types of tumours [33][34][35][36]. Moreover, compared to the earliest radiomic features currently under investigation, these parameters are not limited by clinical applicability and interpretability, being: (i) easily computable by physicians using standard clinical software during a conventional qualitative analysis, (ii) clearly interpretable by clinicians as strictly correlated to biological tumour processes.…”

Section: Introductionmentioning

confidence: 99%

Role of Machine Learning (ML)-Based Classification Using Conventional 18F-FDG PET Parameters in Predicting Postsurgical Features of Endometrial Cancer Aggressiveness

Bezzi

Bergamini

Mathoux

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Purpose: to investigate the preoperative role of ML-based classification using conventional 18F-FDG PET parameters and clinical data in predicting features of EC aggressiveness. Methods: retrospective study, including 123 EC patients who underwent 18F-FDG PET (20092021) for preoperative staging. Maximum standardized uptake value (SUVmax), SUVmean, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were computed on the primary tumour. Age and BMI were collected. Histotype, myometrial invasion (MI), risk group, lymph-nodal involvement (LN), and p53 expression were retrieved from histology. The population was split into a train and a validation set (80–20%). The train set was used to select relevant parameters (Mann-Whitney U test; ROC analysis) and implement ML models, while the validation set was used to test prediction abilities. Results: on the validation set, the best accuracies obtained with individual parameters and ML were: 61% (TLG) and 87% (ML) for MI; 71% (SUVmax) and 79% (ML) for risk groups; 72% (TLG) and 83% (ML) for LN; 45% (SUVmax; SUVmean) and 73% (ML) for p53 expression. Conclusions: ML-based classification using conventional 18F-FDG PET parameters and clinical data demonstrated ability to characterize the investigated features of EC aggressiveness, providing a non-invasive way to support preoperative stratification of EC patients.

show abstract

18F-FDG PET/CT May Predict Tumor Type and Risk Score in Gestational Trophoblastic Disease

Cited by 6 publications

References 40 publications

Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors

Clinical significance of 18F-FDG PET/CT imaging in 32 cases of gastrointestinal stromal tumors

The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review

Role of Machine Learning (ML)-Based Classification Using Conventional 18F-FDG PET Parameters in Predicting Postsurgical Features of Endometrial Cancer Aggressiveness

Contact Info

Product

Resources

About